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Introduction: Although rheumatoid arthritis (RA) is generally a chronic disease, a proportion of RA-patients achieve
disease-modifying antirheumatic drug (DMARD)-free sustained remission, reflecting loss of disease-persistence.
To explore mechanisms underlying RA-persistence, we performed a candidate gene study. We hypothesized that
variants associating with lack of radiographic progression also associate with DMARD-free sustained remission.
Methods: 645 Dutch RA-patients were studied on DMARD-free sustained remission during a maximal follow-up
duration of 10-years. Variants associated with radiographic progression under an additive model in the total
RA-population (Human Leukocyte Antigens (HLA)-DRB1-shared epitope (SE), Dickkopf-1 (DKK1)-rs1896368,
DKK1-rs1896367, DKK1-rs1528873, C5Orf30-rs26232, Interleukin-2 receptor-α (IL2RA)-rs2104286, Matrix metalloproteinase-9
(MMP-9)-rs11908352, rs451066 and Osteoprotegerin (OPG)-rs1485305) were studied. Cox-regression analyses were
performed and Bonferroni correction applied. Soluble IL2Rα (sIL2Rα)-levels were studied. For replication, 622 RA-patients
included in the French Evaluation et Suivi de POlyarthrites Indifférenciées Récentes cohort (ESPOIR)-cohort were
investigated. Results were combined in inverse-variance weighted meta-analysis.
Results: Similar as previously reported, the SE-alleles associated with less remission (hazard ratio (HR) = 0.57, 95 %
confidence interval (95 % CI) = 0.42-0.77, p = 2.72×10−4). Variants in DKK-1, C5orf30, MMP-9 and OPG were not
associated with remission. The IL2RA-rs2104286 minor allele associated with a higher chance on remission (HR = 1.52,
95 % CI = 1.16-1.99, p = 2.44×10−3). The rs2104286 minor allele associated with lower sIL2Rα-levels (p = 1.44×10−3);
lower sIL2Rα-levels associated with a higher chance on remission (HR per 100 pg/L = 0.81, 95 % CI = 0.68-0.95, p = 0.012).
When including rs2104286 and sIL2Rα-levels in one analysis, the HR for rs2104286 was 2.27 (95 % CI = 1.06-4.84, p = 0.034)
and for sIL2Rα 0.83 (95 % CI = 0.70-0.98, p = 0.026). Within ESPOIR, the HR of rs2104286 was 1.31 (95 % CI = 0.90-1.90).
The meta-analysis revealed a p-value of 1.01×10−3.
Conclusion: IL2RA-rs2104286 and sIL2Rα-level associated with RA-persistence. IL2RA variants are known to protect
against multiple sclerosis, diabetes mellitus and RA. Besides HLA-SE, IL2RA-rs2104286 is thus far the only known genetic
variant associated with both joint destruction and RA-persistence. This underlines the relevance of IL2RA for RA.Introduction
Persistent inflammation and progression of joint damage
are the two hallmarks of rheumatoid arthritis (RA). At
present, clinically relevant joint destruction has become
infrequent owing to modern treatment strategies. Despite
this improvement, RA is still a chronic disease in the ma-
jority of patients. Some patients, however, are able to stop
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rence of arthritis; this is called DMARD-free sustained re-
mission. This disease remission reflects the opposite of
RA persistence and frequencies of DMARD-free sustained
remission are reported to vary between 5 and 22 % [1–5].
A thorough comprehension of the mechanisms promoting
disease persistence is required to derive targeted interven-
tions aiming to reduce the chronic nature of RA. At
present, however, the biologic mechanisms underlying dis-
ease persistence are largely unknown.
Only a few risk factors for RA persistence (absence of
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longed symptom duration at treatment start [1, 4, 6, 7].
This risk factor points to a so-called “window of
opportunity” in RA but the processes underlying this asso-
ciation are unidentified. Another risk factor is the pres-
ence of RA-related autoantibodies [1, 2]. Although it is
not exactly known how these autoantibodies exert
their effect, several possibilities have been proposed
[8]. However, the presence of rheumatoid factor (RF)
or anti-citrullinated peptide antibodies (ACPA) ex-
plain only a proportion of the variance in achieving
DMARD-free remission as the large majority of auto-
antibody negative RA-patients have persistent disease
and some patients with auto-antibodies can achieve
remission [9]. One genetic risk factor has been found
associated with arthritis persistence in two European
cohorts: the presence of human leukocyte antigen
(HLA)-DRB1 shared epitope (SE) alleles. This risk fac-
tor presumably acts in the same pathway as ACPA
[1, 2].
To increase the understanding of processes underlying
disease persistence, it is valuable to study patients who
have achieved DMARD-free sustained remission over
time, because this reflects loss of disease persistence.
This study aimed to identify further risk factors for
achieving DMARD-free sustained remission. To this
end, a candidate gene study was performed. To select
genetic candidates, we hypothesized that genetic variants
which are associated with a lack of radiographic joint
damage also associate with DMARD-free sustained re-
mission. Nine variants reported to associate with radio-
graphic progression using an additive model in the total
RA population were studied in relation to DMARD-free
sustained remission in an observational cohort of 645
Dutch RA patients with a maximal follow-up of 10 years.
Significant associations were evaluated for replication in
a second cohort, comprising 622 French RA patients.
One of the nine studied variants was the already known
risk factor HLA-DRB1 SE [1]; this variant was included
in the present study for a complete overview. Another
interesting gene is interleukin-2 receptor alpha (IL2RA);
variants in IL2RA have shown to be associated with a
decreased risk for development of RA [10, 11] and for
the development of other autoimmune diseases such as
multiple sclerosis (MS) [12] and diabetes mellitus (DM)
[13, 14]. Furthermore, rs2104286 in IL2RA is, apart from
the HLA SE, the only genetic factor that associates with
the risk of RA development [10] and with the severity of
radiographic progression within RA [15].
Methods
Patients
RA patients fulfilling the 1987 American College of
Rheumatology (ACR) criteria for RA and included intwo European cohorts were studied. All patients gave
their informed consent, and approval was obtained
from the local medical ethics committees (Medical
Ethical Committee, Leiden University Medical Center
and Institutional Review Board, Montpellier University
Hospital).
Leiden Early Arthritis Clinic cohort
A total of 645 RA patients who were included between
1993 and 2008 were studied. The Leiden Early Arthritis
Clinic (EAC) is a Dutch population-based inception co-
hort that started in 1993 and has been described previ-
ously [2]. Consecutively referred patients were included
when arthritis was present at physical examination and
symptom duration was <2 years. The initial treatment
strategy was different for patients included and diagnosed
during different inclusion periods: patients included in
1993–1995 were initially treated with nonsteroidal anti-
inflammatory drugs (NSAIDs) and then DMARDs were
initiated with delay; patients included in 1996–1998 were
treated early with rather mild DMARDs such as hydroxy-
chloroquine or sulfasalazine; and patients included in
1999–2008 were treated promptly with methotrexate [2].
Evaluation et Suivi de POlyarthrites Indifférenciées
Récentes cohort
Evaluation et Suivi de POlyarthrites Indifférenciées
Récentes (ESPOIR) is a prospective cohort study that
started in 2002, including patients with RA or a sus-
picion to develop RA from 14 French rheumatology
centers. Patient can be included if aged 18–70 years and
at least two swollen joints are present for >6 weeks
and <6 months [16]. In total, 622 RA patients consecu-
tively included between 2002 and 2005 were studied.
In both cohorts at baseline and at the yearly follow-up
visits, questionnaires were completed, physical examin-
ation was performed, and serum samples and radio-
graphs were taken [2, 16].
Outcome
DMARD-free sustained remission was defined as the
sustained absence of arthritis (by physical examination)
after discontinuation of DMARD therapy, including bio-
logics and glucocorticoids (systemic and intra-articular).
In the Leiden EAC cohort, arthritis had to be absent for
the entire follow-up period and at least during 1 year.
For patients with a follow-up longer than 10 years, the
follow-up duration studied was restricted to 10 years.
Medical files of all patients were studied on remission,
and this was determined until 5 April 2012. Patients
who achieved DMARD-free sustained remission initially
but relapsed later over time (n = 2) did not fulfill the
criterion that arthritis should remain absent during
the total follow-up period and were included in the
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up was shorter and restricted to 5 years. To be classified
as having DMARD-free sustained remission, arthritis
had to be absent during at least 1 year after cessation of
DMARDs but not necessarily during the rest of the
follow-up. Here the outcome was assessed reviewing the
structured visits in the database; medical files were not
explored.
Single nucleotide polymorphism selection and
genotyping
Single Nucleotide Polymorphisms (SNPs) selection for
the present study was based on a recently performed lit-
erature review on genetic variants in relation to radio-
graphic progression [17] and the following criteria were
used: (1) the SNP has been reported and replicated or
found significant in meta-analysis of several cohorts to
associate with radiographic joint damage progression.
Furthermore, the observed association with radiographic
progression was done (2) using an additive model and
(3) in the total RA-population and not confined to either
the ACPA-positive or ACPA-negative subgroup. The lat-
ter two criteria were included because it was expected
that performing analyses on DMARD-free sustained re-
mission using a recessive model (in which the group of
patients with two minor alleles is in general small) or in
only a subgroup of patients with or without autoanti-
bodies would have insufficient power to reach statistical
significance. This expectation was substantiated by
power analyses (calculated using PASS 11; NCSS,
Kaysville, UT, USA) based on our cohort (645 RA pa-
tients and 332 ACPA-positive patients). These analyses
revealed that for an 80 % power study for an additive as-
sociation in the total RA population, a hazard ratio (HR)
of 1.5 would be required, but for an 80 % power study
for a recessive association in the total RA population or
for an additive association in only the ACPA-positive
subgroup, HRs would be required of respectively 2.5 and
3.1 which are too high to be expected of SNP effects be-
cause SNPs generally have low effect sizes [11].
Based on the criteria, nine genetic variants were selected
for evaluation in the Leiden EAC cohort: SE in HLA-DRB1
[18], rs1896368, rs1896367, and rs1528873 in Dickkopf-1
(DKK-1) [19], rs2104286 in IL2RA [15], rs26232 in
C5Orf30 [20], rs11908352 in matrix metalloproteinase-9
(MMP-9) [21], rs451066 at chromosome 14 [21], and
rs1485305 in osteoprotegerin (OPG) [22]. Newly identified
SNPs that were significantly associated with DMARD-free
sustained remission in the Leiden EAC cohort were se-
lected for evaluation in the ESPOIR cohort.
Within the Leiden EAC cohort, the HLA-DRB1 alleles
were genotyped using two-digit typing which was com-
plemented by four-digit typing of the DRB1*04 alleles
and by specific probes to detect the presence of the SEsequences in individuals carrying DRB1*01 or DRB1*10
alleles [1]. The following alleles were classified as SE al-
leles: DRB1*0101, DRB1*0102, DRB1*0104, DRB1*0401,
DRB1*0404, DRB1*0405, DRB1*0408, DRB1*0413, DRB
1*0416, DRB1*1001, and DRB1*1402 [23]. Genotyping
data on rs1896368, rs1896367, and rs1528873 in DKK-1
and on rs1485305 in OPG were retrieved using Illumina’s
Golden Gate platform with an overall error rate <2.5 %
and success rates >95 % [19, 22]. rs26232 in C5Orf30 was
genotyped using LightSnp (Roche) with an overall error
rate <1 % and success rates >99 % [20]. Genotyping data
on rs2104286 in IL2RA, rs11908352 in MMP-9, and
rs451066 at chromosome 14 were retrieved using Illumina’s
Immunochip with an overall error rate <1 % and success
rates >98 %. Hardy–Weinberg equilibrium for all SNPs
was p >0.001 [15, 21].
Within the ESPOIR cohort, rs2104286 was genotyped
used allele-specific kinetic polymerase chain reaction ana-
lysis by KBiosciences (UK) using the KASPar method. The
success rate was 97.9 % as described previously [24].
Soluble IL2Rα
In 159 Dutch RA patients, soluble interleukin-2 receptor
alpha (sIL2Rα) levels were evaluated using the standard
sandwich enzyme-linked immunosorbent assay (ELISA)
for sIL2Rα. The ELISA was performed according to the
manufacturer’s recommendations (BD Biosciences). The
serum levels were determined for a previous study on
IL2RA [15]. Samples were collected at a median disease
duration of 4 years (range 1–9 years). For patients who
achieved remission, the sIL2Rα level was determined in
samples taken before remission was achieved.
Statistical analysis
Cox proportional hazard regression analyses were car-
ried out with DMARD-free sustained remission as the
outcome. The date of remission was defined as 1 year
after the date at which DMARDs were withdrawn owing
to remission of disease. Time to remission was the time
from date of inclusion to the date of remission. Patients
who did not achieve remission were censored at the date
when all medical files were studied on the achievement
of DMARD-free sustained remission (5 April 2012).
Analyses were adjusted for age, gender, and inclusion
period (a proxy for the differences over time in applied
treatment strategies), similar to previous reports [2, 3, 19].
Genotypes were tested additively. The association of
sIL2Rα levels (continuous variable) was tested similarly
with an additional adjustment for disease duration at the
time of sample collection. For the genetic variants, the
cutoff for statistical significance was set at p <5.56 × 10−3
(0.05/9 tests) using the Bonferroni correction for multiple
testing. For the test on the serum level, p <0.05 was
considered significant. In the ESPOIR cohort, a similar
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age and gender was performed. ESPOIR RA patients were
diagnosed in a relatively short interval and no adjustments
were made for initial treatment strategies. Results of
the two cohorts were combined in an inverse variance
weighted meta-analysis. Analyses were performed using
IBM SPSS version 20 (Armonk, NY, USA) and STATA
version 12 (College Station, TX, USA).
Results
Patients
The baseline characteristics of the 645 studied RA pa-
tients in the Leiden EAC cohort are presented in Table 1.
During the median follow-up duration of 8.6 years
(interquartile range (IQR) 5.5–10.0 years), 119 patients
achieved DMARD-free sustained remission. The inci-
dence rate for achieving remission was 2.4 per 100
person-years (119 events during the total follow-up of
all patients of 4885 years). The patients who achieved
remission did so after a median disease duration of
4.3 years (IQR 2.9–6.1 years). Patients who achieved
DMARD-free sustained remission had shorter symptom
duration at disease onset (median 12.9 versus 20.3 weeks,
p <0.001) and had less frequent autoantibodies (ACPA-
positivity, 13.0 % versus 61.3 %, p <0.001; RF-positivity,
27.1 % versus 64.7 %, p <0.001) compared with patients
who did not achieve remission (Table 1).
Genetic variants and achieving DMARD-free sustained
remission
Presence of the SE alleles was significantly associated
with DMARD-free sustained remission (p = 2.72 × 10−4).
The HR per SE allele on achieving DMARD-freeTable 1 Patient characteristics of the Leiden EAC cohort
Total (n = 645) DMA
achi
Baseline
Age (years), mean (SD) 56.9 (15.6) 58.8
Female, n (%) 430 (66.7) 74 (
Symptom duration (weeks), median (IQR) 18.8 (10.3–37.3) 12.9
Swollen joint count in 66 joints, median (IQR) 8 (4–13) 9 (4
CRP level (mg/l), median (IQR) 18 (8–42) 18 (
ACPA-positive, n (%) 332 (52.5) 15 (
RF-positive, n (%) 371 (57.8) 32 (
Follow-up
Duration until DMARD-free sustained
remission (years), median (IQR)
4.3 (
ACPA anti-citrullinated peptide antibodies, CRP C-reactive protein, DMARD disease-m
N/A not applicable, RF rheumatoid factor, SD standard deviation
Data were missing on swollen joint count in seven patients, on CRP level in 29 pati
duration in 47 patients
The median symptom duration and the frequencies of ACPA-positivity and RF-posit
achieve DMARD-free sustained remission during follow-up (all p <0.001). The othersustained remission was 0.57 (95 % confidence interval
(95 % CI) = 0.42–0.77) compared with patients without
SE alleles (Table 2; Additional file 1); this finding is in
line with previous reports.
rs1896368, rs1896367, and rs1528873 (all DKK-1),
rs26232 (C5Orf30), rs11908352 (MMP-9), rs451066
(chromosome 14), and rs1485305 (OPG) were not asso-
ciated with DMARD-free sustained remission (Table 2).
rs2104286 in IL2RA significantly associated with achiev-
ing DMARD-free sustained remission (p = 2.44 × 10−3).
The HR per minor C allele for achieving DMARD-free
sustained remission was 1.52 (95 % CI = 1.16–1.99) com-
pared with the reference genotype of patients who were
homozygous for the major T allele (Table 2 and Fig. 1);
hence patients with the minor allele had an increased
chance of achieving remission and, as reported earlier
[15], less radiographic progression.
Genetic variants and achieving DMARD-free sustained
remission in relation to ACPA status
Because genetic risk factors for ACPA-positive and
ACPA-negative RA are different and ACPA-positive and
ACPA-negative RA are considered separate disease en-
tities, we studied whether the observed associations were
independent of ACPA or were restricted to a subset
of RA patients. The analyses of HLA-DRB1 SE and
rs2104286 (IL2RA) were therefore repeated with add-
itional adjustment for ACPA and when stratifying for
ACPA status.
When including both SE and ACPA in one analysis, SE
was not significantly associated (HR = 0.92, 95 % CI =
0.67–1.26, p = 0.61) whilst ACPA remained significant
(HR = 0.13, 95 % CI = 0.072–0.22, p = 7.68 × 10−13),RD-free sustained remission
eved during follow-up (n = 119)
DMARD-free sustained remission not









odifying antirheumatic drug, EAC Early Arthritis Clinic, IQR interquartile range,
ents, on ACPA in 13 patients, on RF in three patients, and on symptom
ivity were significantly different between patients who achieved and did not
baseline characteristics did not differ between the groups
Table 2 Genetic risk factors for severity of joint damage in relation to achieving DMARD-free sustained remission in the Leiden
EAC cohort
Genetic variant (minor allele) Located in/nearby gene(s) (chromosomes) MAF (%) HR per minor allele (95 % CI) p value
Shared epitope [18] HLA-DRB1 (6) 39.6 0.57 (0.42–0.77) 2.72 × 10−4
rs1896368 (G) [19] DKK-1 (10) 45.8 0.98 (0.75–1.28) 0.88
rs1896367 (A) [19] 41.5 0.96 (0.73–1.25) 0.75
rs1528873 (C) [19] 46.7 1.21 (0.93–1.58) 0.15
rs2104286 (C) [15] IL2RA (10) 24.3 1.52 (1.16–1.99) 2.44 × 10−3
rs26232 (T) [20] C5orf30 (5) 28.9 1.08 (0.81–1.44) 0.61
rs11908352 (A) [21] MMP-9 (20) 20.9 0.78 (0.56–1.09) 0.15
rs451066 (A) [21] rs1465788 (14) 19.6 0.87 (0.63–1.21) 0.41
rs1485305 (T) [22] OPG (8) 44.2 1.00 (0.76–1.32) 0.98
CI confidence interval, DKK-1 Dickkopf-1, HLA human leukocyte antigen, HR hazard ratio, IL2RA interleukin-2 receptor alpha, MAF minor allele frequency,
MMP-9 matrix metalloproteinase-9, OPG osteoprotegerin
Analyses were adjusted for age, gender, and inclusion period (as proxy for treatment strategy)
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DMARD-free sustained remission. Similarly, the SE alleles
were not associated with remission in the ACPA-positive
and ACPA-negative subgroups separately (p = 0.84 and
p = 0.51 respectively; Figure S2A in Additional file 2).
Adding ACPA as additional adjustment factor in the
analysis of rs2104286 (IL2RA) in relation to DMARD-
free sustained remission revealed an HR for rs2104286
of 1.47 (95 % CI = 1.12–1.93, p = 5.78 × 10−3), suggesting
that the association of rs2104286 with remission is inde-
pendent of ACPA. Stratified analysis on rs2104286 in
ACPA-positive and ACPA-negative subgroups showed an
HR of 1.82 (95 % CI = 0.88–3.77, p = 0.11) within ACPA-
positive RA and an HR of 1.41 (95 % CI = 1.05–1.89,Fig. 1 rs2104286 in IL2RA in relation to achieving DMARD-free sustained
remission in RA patients of the Leiden EAC cohort. rs2104286 in IL2RA
was significantly associated with achieving DMARD-free sustained
remission in 645 RA patients (p= 2.44 × 10−3). The HR per minor C allele
for achieving remission was 1.52 (95 % CI = 1.16–1.99). The analysis was
adjusted for age, gender, and inclusion period (as a proxy for
treatment strategy). DMARD disease-modifying antirheumatic drug,
IL2RA interleukin-2 receptor alphap = 0.024) within ACPA-negative RA (Figure S2B in
Additional file 2).
sIL2Rα levels and achieving DMARD-free sustained
remission
Previous studies have shown correlations between
rs2104286 in IL2RA and IL2Rα serum levels [25, 26].
Similarly, we have previously studied rs2104286 in IL2RA
and sIL2Rα levels in 159 RA patients from the Leiden
EAC cohort and observed a significant association; the
rs2104286 minor allele associated with lower sIL2Rα
levels (p = 1.44 × 10−3) [15]. We then explored whether
sIL2Rα levels were also associated with DMARD-free sus-
tained remission and observed that lower serum levels
were indeed associated with more remission (p = 0.012);
per 100 pg/ml increase in level, the HR of achieving
remission was 0.81 (95 % CI = 0.68–0.95). In the 159
patients with information on sIL2Rα, rs2104286 was
also associated with DMARD-free sustained remission
(HR = 2.57, 95 % CI = 1.20–5.50, p = 0.015). An analysis
including both rs2104286 and sIL2Rα revealed an HR of
2.27 for rs2104286 (95 % CI = 1.06–4.84, p = 0.034)
and a HR (per 100 pg/ml) of 0.83 for sIL2Rα (95 %
CI = 0.70–0.98, p = 0.026).
Replication of rs2104286 in relation to DMARD-free
sustained remission in the ESPOIR cohort
Subsequently, rs2104286 in IL2RA was studied for repli-
cation in 622 French RA patients. The mean (standard
deviation) age was 48.8 (12.3) years, 76 % were female,
the median (IQR) symptom duration was 22 (13–33)
weeks, and 46 % were ACPA-positive. After a median
(IQR) follow-up duration of 5.0 (3.0–5.0) years, 67 pa-
tients achieved DMARD-free sustained remission after a
median follow-up duration of 1.5 (0.7–3.0) years. The in-
cidence rate for remission was 2.7 per 100 person-years
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The number of events (n = 67) was lower than that of
the first cohort, so the power to find significance was ex-
pected to be less than that of the first phase. Evidence of
a tendency in the same direction was still considered
relevant and Cox regression analyses on rs2104286 and
remission were performed. The HR per minor C allele
for achieving DMARD-free sustained remission was 1.31
(95 % CI = 0.90–1.90, p = 0.16) compared with the com-
mon genotype. Although not reaching statistical signifi-
cance, this indicates that, similar to the Leiden EAC
cohort, patients with the minor allele had an increased
chance of achieving remission (Fig. 2a). When addition-
ally adjusting the analysis for ACPA, the HR was 1.37
(95 % CI = 0.95–1.97, p = 0.097). Meta-analysis of theFig. 2 rs2104286 in IL2RA in relation to achieving DMARD-free sustained
remission in RA patients of the ESPOIR cohort and in meta-analysis of
the Leiden EAC and ESPOIR cohorts. a In 622 RA patients of the ESPOIR
cohort, the HR per minor C allele for achieving remission was 1.31
(95 % CI = 0.90–1.90, p = 0.16). The analysis was adjusted for age and
gender. The minor allele frequency in the ESPOIR cohort was 23.2 %.
b Results of the Leiden EAC and ESPOIR cohorts were combined in
an inverse variance weighted meta-analysis: I2 = 0.0 %, p = 0.53, fixed-
effect p = 1.01 × 10−3, random-effects p = 1.01 × 10−3. CI confidence
interval, DMARD disease-modifying antirheumatic drug, EAC early
arthritis clinic, ESPOIR Evaluation et Suivi de POlyarthrites Indifférenciées
Récentes, HR hazard ratio, IL2RA interleukin-2 receptor alpharesults of the Leiden EAC and ESPOIR cohorts revealed
a fixed-effect p value of 1.01 × 10−3 (Fig. 2b).
Discussion
The biological mechanisms driving disease chronicity in
RA are largely unidentified. We therefore aimed to de-
termine genetic risk factors for disease persistence in
RA. Because of the low frequency of DMARD-free sus-
tained remission (reflecting loss of disease persistence)
and because of the lack of multiple large cohorts with
data on this disease outcome, we were not able to per-
form a hypothesis-free genome-wide association study
or to analyze the whole Immunochip. We used a can-
didate gene approach instead and hypothesized that
genetic variants which associated with the severity of
joint damage also associated with disease persistence. In
addition to the previously reported association between
the HLA-DRB1 SE alleles and DMARD-free sustained
remission (reflecting loss of disease persistence), we
demonstrated that rs2104286 in IL2RA associated with
DMARD-free sustained remission; this minor allele that
was previously associated with less severe radiographic
progression [15] was associated with a higher chance of
DMARD-free sustained remission. Also, the lower level of
sIL2Rα observed in the presence of the rs2104286 minor
allele associated with a higher chance of DMARD-fee sus-
tained remission. Altogether the present data from two
observational cohorts indicate that the IL2RA minor allele
is not only protective for the severity of radiographic
progression but also predisposes to a less persistent course
of RA.
IL2RA encodes the α-chain of the high-affinity IL-2 re-
ceptor (CD25) which is expressed on and upregulated
after stimulation in many immune cells, including regu-
latory T cells (Tregs) [27, 28]. Variants in IL2RA are also
associated with the risk of development of RA [10, 11]
and other autoimmune diseases such as MS [12] and
type 1 DM [13, 14]. sIL2Rα is produced by proteolytic
cleavage of cell-bound IL2Rα and is considered reflective
of the extent of activation and expansion of T cells
[26, 29, 30]. Other studies reported that the minor allele
of rs2104286 correlated with lower sIL2Rα levels in
patients and healthy individuals [15, 25, 26]. In our pre-
vious study, rs2104286 was no longer associated with
joint destruction after including sIL2Rα in the analysis,
suggesting that the SNP might act in the same path that
influenced the serum levels [15]. In present study, the
genetic and serological marker remained significantly
associated with DMARD-free sustained remission. This
might suggest that IL2RA exerts part of its effect by a
path which does not influence sIL2Rα levels. However,
association studies cannot answer causality questions.
RA is considered to consist of ACPA-positive and
ACPA-negative subentities, each with different genetic
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served association was present in one or both subsets,
stratified analyses were performed. Although these ana-
lyses were assumed to have insufficient power (owing to
lower number of patients, and in ACPA-positive RA also
a low frequency of remission), they were performed to
gain insight into the data. Adjusting for ACPA is more
powerful. The association of rs2104286 with DMARD-
free sustained remission was independent of ACPA.
In the present study we did not fine-map the IL2RA
region in relation to DMARD-free sustained remission
because we expected to have insufficient power to find
statistical significance after correcting for >400 tests.
Previously the IL2RA region was fine-mapped in relation
to joint damage progression, which is a more powerful
analysis than the present survival analysis because it
makes use of repeated measurements over time.
rs12722508 was identified as the SNP with the strongest
association [15]. Evaluating rs12722508 in relation to
DMARD-free sustained remission revealed a lower p value
and larger HR for rs12722508 (HR = 1.93, p = 7.90 × 10−4)
compared with rs2104286 (HR = 1.52, p = 2.44 × 10−3). Al-
though fine-mapping was not performed in this study,
these data strengthen the finding on IL2RA and DMARD-
free sustained remission.
At present, there is not much literature on the descrip-
tion of RA persistence or chronicity. In the present
study, patients who were unable to reach DMARD-free
sustained remission were considered to have persistent
disease. Although other definitions for RA persistence
can be used, we have chosen the absence of DMARD-
free sustained remission as the outcome because it is a
strict definition and the closest available proxy for cure
of the disease.
The majority of the studied patients had persistent
disease and did not achieve remission. Recently, we re-
ported that the chance of achieving DMARD-free sus-
tained remission in clinical practice has become a more
feasible outcome with up-to-date treatment strategies
[5]. The Leiden EAC patients who were evaluated in the
present study were included during the period 1993–2006.
Treatment strategies have changed over time in these pa-
tients and indeed patients included in later periods had a
higher chance of achieving DMARD-free sustained remis-
sion (data not shown). All analyses in the present study
were adjusted for the inclusion period as a proxy for the
initially applied treatment strategy, and the results obtained
for IL2RA were thus independent of the effect of changes
in treatment strategies.
Another potential limitation is that we evaluated data
from longitudinal observational cohort studies. These
data reflect the daily care of patients and not only deci-
sions to start DMARDs but also decisions to stop
DMARDs were left to the patients’ and rheumatologists’decisions and not protocolized. In the ESPOIR cohort,
mainly in the first years of its existence, quitting
DMARD therapy was uncommon. Consequently, the ob-
served frequency of DMARD-free sustained remission
may be underestimated. This may be one of the explana-
tions contributing to a lower incidence of DMARD-free
sustained remission in the ESPOIR cohort. In addition,
whether DMARD-free sustained remission was achieved
was determined slightly differently in the cohorts. In the
Leiden EAC cohort, all medical files were checked to en-
sure that DMARD-free sustained remission was present.
In the ESPOIR cohort, data from the structured visits
with yearly intervals were studied. It is possible that
more patients included in the ESPOIR cohort would
have achieved DMARD-free sustained remission when
all information present in medical files was evaluated.
Thirdly, the follow-up duration was shorter in the
ESPOIR cohort. Differences in common practice for
discontinuing DMARD therapy, however, might be the
most important cause for the higher frequency of
DMARD-free sustained remission in the Leiden EAC co-
hort than in the ESPOIR cohort. Nonetheless, there was
a strong tendency in the data from the ESPOIR cohort
validating the importance of IL2RA for the disease
course in RA.
The SE alleles were strongly associated with sustained
DMARD-free remission. A similar result was previously
reported (although using a dominant model instead of
an additive model). We here observed that this associ-
ation was not independent of ACPA, suggesting that the
SE alleles act in the same path as ACPA. This finding is
similar to that observed for SE, ACPA, and radiographic
progression [33].
The studied variants in DKK-1, C5Orf30, MMP-9, and
OPG were not associated with DMARD-free sustained
remission. Although power issues might have contrib-
uted to some negative findings, the absence of an associ-
ation of these risk factors for radiographic progression
with DMARD-free sustained remission suggests that the
mechanisms driving joint damage progression and dis-
ease persistence are partially different.
At present >100 genetic susceptibility factors are known
and several genetic risk factors for radiographic progres-
sion have been identified [11, 34]. These factors were
largely dissimilar; only the HLA-DRB1 SE alleles and
IL2RA were present in both lists of risk factors. Interest-
ingly, the current study determined that both factors are
also associated with persistence of RA. This suggests that
both variants are of crucial importance for the processes
mediating RA development and progression.
IL-2/IL-2 receptor signaling is important during im-
mune responses of both effector T cells and Tregs.
Quantitatively, Tregs require less IL-2/IL-2 receptor sig-
naling than effector T cells to support their development
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nomodulation with low-dose IL-2 in other autoimmune
diseases have been published, showing efficacy on upregu-
lation of Tregs [34, 35] and improved clinical outcome
[37]. Monoclonal anti-CD25 antibodies (daclizumab) have
also been shown effective in reducing disease activity in
autoimmune diseases [38]; this effect is not only ascribed
to direct effects on T cells but also on natural killer (NK)
cells and dendritic cells [38]. To the best of our knowledge
there are no data on IL-2 treatment for RA. However, if
low-dose IL-2 treatment is effective, the results of IL-2
therapy in RA might also be dependent on the IL-2 recep-
tor status of the patient, which is genetically determined.
Hence, the IL2RA genotype presumably affects the re-
sponse of IL-2 therapy and might be relevant for personal-
ized medicine.Conclusion
Genetic studies are useful because they can point to
mechanisms that are pivotal for disease development or
disease progression. This study observed that rs2104286
in IL2RA and the sIL2Rα level are associated with RA
persistence. Besides the HLA-DRB1 SE, IL2RA is the
only genetic risk factor for development of RA and for
both radiographic progression and persistence. This un-
derlines the relevance of IL2RA for RA. Further research
is needed to gain more insight into the underlying
mechanisms of arthritis persistence.Additional files
Additional file 1: Figure S1. Showing SE alleles in HLA-DRB1 in relation
to achieving DMARD-free sustained remission in RA patients in the
Leiden EAC cohort. SE alleles were significantly associated with achieving
DMARD-free sustained remission in 616 RA patients with HLA-DRB1
genotyping data (p = 2.72 × 10−4). The HR per SE allele for achieving
remission was 0.57 (95 % CI = 0.42–0.77). The analysis was adjusted for age,
gender, and inclusion period (as proxy for treatment strategy). (PDF 52 kb)
Additional file 2: Figure S2. Showing genetic variants in relation
to achieving DMARD-free sustained remission in ACPA-positive and
ACPA-negative RA patients from the Leiden EAC cohort. SE in ACPA-positive:
HR per SE allele = 0.92 (95 % CI = 0.42–2.03). SE in ACPA-negative: HR per SE
allele = 0.89 (95 % CI = 0.63–1.25). rs2104286 (IL2RA) in ACPA-positive: HR per
minor allele = 1.82 (95 % CI = 0.88–3.77). rs2104286 (IL2RA) in ACPA-negative:
HR per minor allele = 1.41 (95 % CI = 1.05–1.89). All analyses were adjusted
for age, gender, and inclusion period (as proxy for treatment strategy). Note
that the y axes of the ACPA-positive and ACPA-negative subgroups are
different. (PDF 218 kb)
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